INTRODUCTION {#s1}
============

The treatment of human cancer has shifted toward a precision medicine paradigm that increasingly relies on the genomic annotation of each patient's tumor tissue. This trend is supported by the clinical observation that tumor responses to signal transduction inhibitors often are greatest in tumors that harbor mutations in the targeted pathway, by the discovery of specific drug-resistance mutations in tumors that resume growth during therapy, and by the recent association between effective immunotherapy and tumor-specific missense mutations. Outgrowth of drug-resistant tumor cell clones during therapy can limit the clinical relevance of the initial tumor profile and has motivated the development of technologies that can track the evolution of the cancer genome in accessible body fluids.^[@B1]^

Cancers that affect the central nervous system (CNS) pose a particular challenge because of the difficulty in accessing tumor tissue and the inability to detect circulating tumor DNA in the plasma of affected patients.^[@B2]^ One potential source of tumor-derived DNA in patients with CNS tumors is cerebrospinal fluid (CSF), which circulates through the CNS. In patients whose primary tumor had disseminated to the CNS, several groups were able to identify selected mutations of the primary tumor in CSF by using polymerase chain reaction detection techniques.^[@B3]-[@B7]^ A recent study collected CSF during the resection of primary brain or spinal cord tumors and reported that 26 of 35 (74%) samples contained tumor DNA, which was defined as the presence of at least one mutation in the primary tumor.^[@B8]^ All patients were previously untreated, and the detection of mutations in the CSF was guided by prior profiling of the primary tumor. A separate study used targeted next-generation sequencing to reveal oncogenic mutations in tumor-derived DNA from CSF in a limited number of patients.^[@B9]^ Together, these studies suggest that the shedding of tumor DNA into the CSF may be a frequent occurrence in CNS cancers, but it is unclear whether comprehensive sequencing of CSF can routinely and reliably identify clinically relevant genomic alterations without prior knowledge of mutations in the primary tumor and whether this can be done successfully without a need for surgery in a large series of patients. The goal of the current study was to explore whether routine lumbar puncture and high-throughput sequencing of CSF could identify tumor-associated DNA in patients with known or suspected CNS involvement and provide clinically meaningful insights into the biology of these tumors and their treatment response.

MATERIALS AND METHODS {#s2}
=====================

CSF Collection and Preparation {#s3}
------------------------------

We collected CSF samples from 53 patients with cancer who underwent evaluation for leptomeningeal metastasis between August 2014 and February 2015. Fifty-two (98%) CSF samples were obtained by lumbar puncture and one from an Ommaya reservoir. All patients signed informed consent for use of leftover CSF for research purposes under protocols approved by the Memorial Sloan Kettering (MSK) Cancer Center Institutional Review Board. Within 2 to 3 hours of CSF collection, 5 mL of CSF was placed on ice and centrifuged at 1,000 × *g* at 4°C for 5 minutes. The supernatant was aseptically transferred to prelabeled cryotubes, and the cell pellet was resuspended in 1 mL of RPMI + 20% fetal bovine serum + 20% dimethyl sulfoxide. All tubes were stored at −70°C.

Extraction of Cell-Free DNA {#s4}
---------------------------

The minimum amount of the CSF tested was 2 mL (mean, 5 mL; range, 2 to 7 mL). Stored CSF samples were thawed at room temperature and centrifuged at 10,000 × *g* for 30 minutes at 4°C to remove residual precipitated cellular components and various particles. The method applied for the extraction of cell-free DNA (cfDNA) was based on the manufacturer's protocol for the QIAamp Circulating Nucleic Acid Kit (catalog \#55114; QIAGEN, Valencia, CA). Briefly, 5 mL of CSF was mixed with 500 μL of protease K and 4 mL of buffer ACL. After incubation at 60°C for 30 minutes, 9 mL of buffer ACB was added and then incubated on ice for 5 minutes. The mixture was filtered through a minicolumn and rinsed by ACW1, ACW2, and ethanol. DNA was eluted in 100 μL of buffer AVE.

Targeted Capture and Sequencing {#s5}
-------------------------------

All samples were subjected to molecular analysis by using the MSK-Integrated Molecular Profiling of Actionable Cancer Targets (IMPACT) assay,^[@B10]^ which captures all protein-coding exons of 341 cancer-associated genes as well as 33 introns in 14 recurrently rearranged genes. The Illumina libraries were constructed with KAPA Hyper Prep Kit followed by ligation with 5 μM adaptor concentration (catalog \#KK8504; Kapa Biosystems, Wilmington, MA). Libraries of this targeted capture were pooled in equimolar concentrations and sequenced on an Illumina HiSeq 2500 system (Illumina, San Diego, CA) as paired end 100--base pair reads.

Genomic Analysis {#s6}
----------------

Analysis for the targeted sequencing data was performed as described previously.^[@B10]^ In brief, demultiplexed FASTQ files were aligned to GRCh37 reference human genome assembly by using BWA-MEM (Burrows-Wheeler Aligner software version 0.7.5a, <http://arxiv.org/abs/1303.3997>), and polymerase chain reaction duplicates were identified with use of the MarkDuplicates tool in Picard Tools software version 1.96 (<https://github.com/broadinstitute/picard>). Regions in the genome covered by more than 20× coverage were identified by using the FindCoveredIntervals from the Genome Analysis Toolkit^[@B11]^ and subjected to indel realignment by Assembly-Based ReAligner version 0.92 software.^[@B12]^ Variant calling was performed in paired tumor/normal mode by using MuTect software version 1.1.4^[@B13]^ for single nucleotide variants and SomaticIndelDetector^[@B11]^ and Pindel software version 0.2.5a7^[@B14]^ for small insertions and deletions. All variants were then annotated using ANNOVAR software version 527.^[@B15]^ For CSF cfDNA and cell pellets without a genetically matched normal, variants were called against a single pool of unmatched normal samples, and variants were filtered if the minor allele frequency was \> 0.0004 in any subpopulation in the 1000 Genomes Project cohort^[@B16]^ or Exome Aggregation Consortium^[@B17]^ because these are more likely to be common population polymorphisms than somatic mutations. All candidate mutations and indels in the Data Supplement were called automatically by using the bioinformatics pipeline described previously and subsequently reviewed manually by using the Integrative Genomics Viewer^[@B18]^ to eliminate potential false-positive calls. The current framework can be found at <https://github.com/rhshah/impact-pipeline>.

Copy number variation was identified by analyzing sequence coverage of targeted regions in a tumor sample compared with a standard diploid normal sample after performing sample-wide LOWESS normalization for guanine-cytosine percentage across exons and normalizing for global differences in on-target sequence coverage, as previously described.^[@B10]^ Somatic structural aberrations were identified by using DELLY software.^[@B19]^ All candidate somatic structural aberrations were filtered, annotated by using in-house tools, and manually reviewed with Integrative Genomics Viewer.^[@B18]^ Figures were created and modified by using R for statistical computing and graphics (R Development Core Team) and Adobe Illustrator (<http://www.adobe.com/products/illustrator.html>) by using free templates designed by Freepik (<http://freepik.com>).

RESULTS {#s7}
=======

Comparison of Mutation Detection in CSF cfDNA Versus Cell-Pellet DNA {#s8}
--------------------------------------------------------------------

As a first step toward developing a robust mutation detection method, we examined which component of CSF was most sensitive for the detection of the most common cancer-associated genetic alterations. Because CSF in healthy individuals contains a small number of WBCs (0 to 5/μL), we were concerned that germline DNA from normal or reactive WBCs would dilute the signal from tumor-derived DNA. To address this question, we centrifuged eight freshly collected CSF samples, separated the cell pellet from the supernatant ([Fig 1A](#F1){ref-type="fig"}), and compared DNA yields and detection of cancer-associated mutations in each aliquot. To increase the likelihood of detecting tumor-derived DNA, these pilot experiments focused on eight patients with an established diagnosis of CNS metastasis from solid tumors on the basis of typical radiographic findings (n = 8) or detection of tumor cells in the CSF (n = 7). In each patient, the primary tumor was known to harbor a clinically relevant driver mutation. There was a trend toward higher DNA yields from CSF pellets (mean, 280 ng) than from the CSF supernatants (mean, 27 ng), but this difference was not statistically significant (*P* = .22), and we achieved high unique sequence coverage of sequencing libraries from both pellets (mean, 746×) and supernatants (mean, 444×).

![Comparison of tumor-derived DNA from cerebrospinal fluid (CSF) cell pellet and supernatant. (A) Schematic of separation of CSF pellet and supernatant. Cellular DNA is isolated from the pellet, and cell-free DNA (cfDNA) is isolated from the supernatant. (B) Variant allele frequencies for known mutations in CSF cfDNA and pellet DNA. (C) Log2 ratios of normalized sequence coverage for target exons in CSF cfDNA and pellet DNA for patient 8. Greater than 10-fold amplification of *HER2* was observed in CSF cfDNA, whereas *HER2* amplification was barely detectable in pellet DNA. (D) Evidence of *EML4-ALK* gene fusion in CSF cfDNA and pellet DNA for patient 6. Read pairs supporting the fusion (red) were visualized by using the Integrative Genomics Viewer. Pt, patient ID.](JCO666487f1){#F1}

We next compared our ability to detect sequence mutations, copy number alterations, and structural rearrangements in CSF pellet DNA and CSF cfDNA with our in-house sequencing assay (MSK-IMPACT), which interrogates 341 clinically relevant cancer genes. MSK-IMPACT has been extensively validated in a cohort of \> 300 distinct positive-control tumors^[@B10]^ and has been approved as a clinical test by the New York State Department of Health. All four patients with known single nucleotide substitutions exhibited a higher percentage of sequence reads that harbored the mutant allele in the CSF cfDNA compared with the CSF pellet DNA. These included two patients with *BRAF* V600E mutant melanoma, one with non--small-cell lung cancer (NSCLC) with *EGFR* L858R mutation, and one with NSCLC with *KRAS* G12C mutation ([Fig 1B](#F1){ref-type="fig"}). In terms of gene copy number alterations, we observed an 11-fold amplification of the *HER2* gene locus in CSF cfDNA from one patient with *HER2*-amplified breast cancer. In contrast, the copy number plot obtained from pellet DNA of the same CSF sample was markedly blunted, and the *HER2* gene amplification was barely detectable ([Fig 1C](#F1){ref-type="fig"}). In another patient with breast cancer with known loss of PTEN, we detected a homozygous deletion at the *PTEN* locus on chromosome 10q in the CSF cfDNA sample but not in the cell pellet DNA (Appendix [Fig A1](#FA.1){ref-type="fig"}, online only). Two patients with NSCLC harbored rearrangements that involved anaplastic lymphoma kinase (ALK) in the primary tumor, which was supported by 39 and 102 DNA fragments in CSF cfDNA compared with 14 and 102 DNA fragments in the respective CSF pellet DNA ([Fig 1D](#F1){ref-type="fig"}; Appendix [Fig A2](#FA.2){ref-type="fig"}, online only). In summary, known molecular alterations from the primary tumors were readily detectable in all eight (100%) CSF cfDNA samples but only in five (63%) CSF pellet DNA samples. In every case, the evidence that supported the key alteration was greater in cfDNA than in pellet DNA (Appendix [Table A1](#TA.1){ref-type="table"}, online only), which suggests that a higher proportion of the cfDNA is tumor derived.

CSF cfDNA in Various Types of CNS Cancer {#s9}
----------------------------------------

Based on results from our pilot study, we used cfDNA as the DNA source for all subsequent analyses of genomic alterations in CSF and extended the study to 45 additional CSF samples from patients with cancer referred to our neuro-oncology clinic. All patients underwent standard-of-care diagnostic testing with magnetic resonance imaging (MRI) of the brain and CSF cytology. Together with the samples from our pilot project, the current study comprised 53 CSF samples from 41 patients with solid tumors and 12 with primary brain tumors. Of the 41 with solid tumors, 32 had CNS involvement by cancer. Nine with a variety of cancer types had no evidence of CNS involvement (ie, MRI and CSF cytology negative) and had an organ-confined primary tumor (n = 6) or metastatic cancer to non-CNS sites (n = 3; [Table 1](#T1){ref-type="table"}).

###### 

Characteristics of 53 Patients With CNS Involvement and Primary Tissue Cancer for Which CSF Cell-Free DNA Was Extracted and Analyzed

![](JCO666487t1)

  Patient No.            Primary Tumor                  CNS Involvement             Original Specimen (molecular pathology)                                 CSF (MSK-IMPACT)
  ---------------------- ------------------------------ --------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------
  Solid tumors                                                                                                                                              
   1                     NSCLC                          Brain metastases            *EGFR* L858R (bone, Sequenom)                                           *EGFR* L858R (56%)
   2                     NSCLC                          Brain metastases            *EGFR* L858R (lung, Sequenom)                                           *EGFR* T790M (2.5%), *EGFR* L858R (76%)
   3                     NSCLC                          Brain metastases            *EGFR* exon 19 del (chest wall, Sequenom)                               *EGFR* T790M (2.8%), *EGFR* 745_750 del (37%)
   4                     NSCLC                          Brain metastases            *EGFR* L858R (lung, Sequenom)                                           *KRAS* G12A (19%), *EGFR* L858R (65%)
   5                     NSCLC                          Brain metastases            *KRAS* G12C (c34 G\>T) (lung, Sequenom)                                 *KRAS* G12C (96%), *CDKN2B* del (log2, −2.9)
   6                     NSCLC                          Brain metastases            *ALK* rearrangement (lung, ND)                                          *EML4-ALK* fusion (39 reads)
   7                     NSCLC                          Leptomeningeal metastases   *EML4-ALK* fusion (lung, FM)                                            *EML4-ALK* fusion (102 reads)
   8                     Breast                         Brain metastases            *HER2* AMP (breast, FISH)                                               *PIK3CA* H1047R (38%), *HER2* AMP (log2, 3.5)
   9                     Breast                         Brain metastases            *HER2* AMP (breast, FISH)                                               *HER2* AMP (log2, 2.6)
   10                    Breast                         Brain metastases            HER2 positive (breast, IHC 3+)                                          *HER2* AMP (log2, 2.6)
   11                    Breast                         Brain metastases            No molecular profiling performed                                        *EGFR* AMP (log2, 3.1), *PIK3CA* H1047R (28%)
   12                    Breast                         Brain metastases            *TP53* V272M (56%), *PTEN* del (log2, −2.0; lymph node, MSK-IMPACT)     *TP53* V272M (81%), *PTEN* del (log2, −2.97)
   13                    Breast                         Brain metastases            ER positive, PR/HER2 negative (thyroid metastases, IHC)                 *PIK3CA* E545K (26%)
   14                    Melanoma                       Brain metastases            *BRAF* V600E (skin, ND)                                                 *BRAF* V600E (24%)
   15                    Melanoma                       Leptomeningeal metastases   *BRAF* V600E (skin, ND)                                                 *PTEN* del (log2, −XYZ), *BRAF* V600E (96%)
   16                    Melanoma                       Brain metastases            *BRAF* V600E (skin, ND)                                                 *NRAS* G12R (3%), *PTEN* del (log2, −3.0), *BRAF* V600E (47%)
   17                    Bladder cancer                 Brain metastases            No molecular profiling performed                                        *AKT2* AMP (log2, 3.37), *TP53* R158L (43%)
   18                    Gastroesophageal               Leptomeningeal metastases   No molecular profiling performed (MSK-IMPACT failure)                   *HER2* AMP (log2, 2.4), *FGFR2* (log2, 3.6)
   19                    Neuroendocrine                 Brain metastases            No molecular profiling performed                                        *MYCN* AMP (log2, 4.1)
   20                    Ovarian                        Brain metastases            *BRCA1* insC (blood, Myriad Genetics laboratory)                        *BRCA1* Q1756fs (53%), *CDKN2B* del (log2, −2.1)
   21                    Ovarian                        Leptomeningeal metastases   No molecular profiling performed                                        Negative
   22                    Breast                         Brain metastases            No molecular profiling performed                                        Negative
   23                    Breast                         Brain metastases            *HER2* AMP (breast, FISH)                                               Negative
   24                    Breast                         Brain metastases            *ESR1* Y537S (62%), CCND1 AMP (log2, 1.5; breast, MSK-IMPACT)           Negative
   25                    Breast                         Brain metastases            *RB1* L343Sfs\*3 (liver, MSK-IMPACT)                                    Negative
   26                    Breast                         Brain metastases            PIK3CA R108 del (39%), CCND1 AMP (log2, 1.0; soft tissue, MSK-IMPACT)   Negative
   27                    NSCLC                          Brain metastases            No molecular profiling performed                                        Negative
   28                    NSCLC                          Brain metastases            No molecular profiling performed                                        Negative
   29                    SCLC                           Brain metastases            No molecular profiling performed                                        Negative
   30                    NSCLC                          None                        *ALK* rearrangement (lung, FISH)                                        Negative
   31                    Melanoma                       Brain metastases            *BRAF* V600E (skin, Sequenom)                                           Negative
   32                    Melanoma                       Brain metastases            *BRAF* V600K (lymph node, Sequenom)                                     Negative
   33                    Melanoma                       None                        *NRAS* (lung, Sequenom)                                                 Negative
   34                    Thyroid                        Brain metastases            *NRAS* TP53 (thyroid, PCR)                                              Negative
   35                    Thyroid                        None                        No molecular profiling performed                                        Negative
   36                    Rectal                         None                        No molecular profiling performed                                        Negative
   37                    Prostate                       None                        No mutation found (prostate, MSK-IMPACT)                                Negative
   38                    Prostate                       None                        *NOTCH1* R1758H (13%; prostate, MSK-IMPACT)                             Negative
   39                    Renal                          None                        No molecular profiling performed                                        Negative
   40                    Renal                          None                        No molecular profiling performed                                        Negative
   41                    Liposarcoma                    None                        No molecular profiling performed                                        Negative
  Primary brain tumors                                                                                                                                      
   42                    Anaplastic astrocytoma         N/A                         *IDH1* R132H (IHC), *PIK3CA* H1047R                                     *IDH1* R132H (38%), PTEN R130\* (25%)
   43                    Glioblastoma                   N/A                         No molecular profiling performed                                        *PIK3CA* V344M (6%)
   44                    Glioblastoma                   N/A                         PTEN loss (IHC)                                                         *PTEN* Y336_F337 delins\* (14%), *EGFR* AMP (log2, 3.4)
   45                    Anaplastic oligodendroglioma   N/A                         *IDH1* R132H (IHC),1p/19q del (FISH)                                    *IDH1* R132H (44%), 1p/19q del (log2, −0.8)
   46                    Glioblastoma                   N/A                         PTEN loss, *CDK4* AMP, *CLI1* AMP, TP53, TERT, SPTA1 (FM)               *CDK4* AMP (log2, 2.4)
   47                    Brainstem glioma               N/A                         No molecular profiling performed                                        *PDGFRA* AMP (log2, 2.0), *CDKN2B* del (log2, −3.0)
   48                    Glioblastoma                   N/A                         No molecular profiling performed                                        Negative
   49                    High-grade glioma              N/A                         No molecular profiling performed                                        Negative
   50                    Oligodendroglioma              N/A                         No molecular profiling performed                                        Negative
   51                    Anaplastic ependymoma          N/A                         *CDKN2A* Y44\* (8%; MSK-IMPACT)                                         Negative
   52                    Anaplastic oligodendroglioma   N/A                         1p/19q del (FISH)                                                       Negative
   53                    Anaplastic oligodendroglioma   N/A                         *IDH1* R132H (IHC), 1p/19q del (FISH)                                   Negative

Abbreviations: ALK, anaplastic lymphoma kinase; AMP, amplification; CNS, central nervous system; CSF, cerebrospinal fluid; del, deletion; delins, deletion/insertion; EGFR, epidermal growth factor receptor; ER, estrogen receptor; FISH, fluorescent in situ hybridization; FM, Foundation Medicine; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ins, insertion; MSK-IMPACT, Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets; N/A, not applicable; ND, not determined; NSCLC, non--small-cell lung cancer; PCR, polymerase chain reaction; PR, progesterone receptor; SCLC, small-cell lung cancer.

CSF from patients with brain metastases and positive CSF cytology (n = 13) showed significantly higher DNA yields, sequence library complexity, and unique sequence coverage than CSF from patients with negative CSF cytology (Appendix [Fig A3](#FA.3){ref-type="fig"}, online only). Overall, we achieved ≥ 100× coverage in 12 of 16 patients with positive CSF cytology (average unique median coverage, 397×) and in four of 25 with negative CSF cytology (average unique median coverage, 175×; *P* \< .001). The patients who did not have detectable levels of CSF cfDNA had lower overall DNA yields (13 *v* 90 ng) and lower unique sequence coverage (42× *v* 464×), which reflected the smaller quantities of tumor-derived DNA and low background levels of nontumor-derived DNA in CSF. For patients with primary brain tumors, we achieved ≥ 100× coverage in five of 12 patients (average unique median coverage, 391×). CSF from most of these patients (11 of 12) had negative cytology.

With MSK-IMPACT, we detected high-confidence somatic alterations in 63% of patients with CNS metastases and solid tumors and 50% of patients with primary brain tumors. None of the CSF samples from patients with cancer without CNS involvement (n = 9) showed tumor-derived molecular alterations. Within the group with CNS metastases, high-confidence somatic alterations were found in all 16 (100%) patients with positive CSF cytology and four of 16 (25%) with negative CSF cytology with radiographic evidence for CNS metastases (*P* = .1; [Fig 2](#F2){ref-type="fig"}). No statistically significant relationship was found between the presence of tumor-associated DNA in CSF and patient age or sex, histology of the primary tumor, presence of metastases outside the CNS, prior treatment, or site of the CNS metastases (Appendix [Table A2](#TA.2){ref-type="table"}, online only).

![Detection of tumor-associated mutations in CSF in patients with solid tumors and primary brain tumors. Inset shows the percentage of success in finding somatic alterations in patients with central nervous system (CNS) metastasis with positive and negative cerebrospinal fluid (CSF) cytology.](JCO666487f2){#F2}

Clinical Significance of Mutations in CSF cfDNA {#s10}
-----------------------------------------------

To interpret the genetic alterations in CSF cfDNA within their clinical context, we compared them to molecular profiling results of earlier biopsy specimens taken from the same patient. For many patients, the primary tumor sample had been examined by using a range of clinically approved laboratory tests. Mutations in CSF cfDNA were called de novo on the basis of a bioinformatics pipeline without prior knowledge of the alterations seen in tissue. In all available patients in whom CSF cfDNA was detectable, the CSF cfDNA sample was concordant with the previously identified molecular alteration ([Table 1](#T1){ref-type="table"}; Appendix [Table A3](#TA.3){ref-type="table"}, online only).

An important potential application of CSF genomic profiling is the identification of drug-resistance mechanisms in patients whose primary tumor responded to genotype-directed targeted cancer therapy but then progressed in the CNS. Of note, secondary kinase mutations can confer drug resistance at low allelic frequency and, therefore, can be difficult to detect.^[@B20]^ We hypothesized that the coverage of the MSK-IMPACT sequencing assay is sufficiently deep and broad to uncover a range of drug-resistance mutations in CSF cfDNA. In a group of 12 cohort patients in whom progressive CNS disease developed during treatment with inhibitors of oncogenic kinases (epidermal growth factor receptor \[EGFR\], ALK, human epidermal growth factor receptor 2 \[HER2\], or BRAF), we identified drug-resistance mutations in the CSF in four (one third). CSF cfDNA from two patients with EGFR-mutant lung cancer (patients 2 and 3 in [Fig 3A](#F3){ref-type="fig"}) showed an *EGFR* T790M mutation, the most common cause of acquired resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs) in NSCLC.^[@B21]^ Tumors obtained from both patients before EGFR TKI therapy were negative for the *EGFR* T790M mutation in a Sequenom-based genotyping assay, and the absence of the T790M mutation was confirmed in the pretreatment tissue by MSK-IMPACT in patient 2. In a third patient with EGFR-mutant NSCLC and acquired erlotinib resistance in the CNS, we identified an activating *KRAS* G12A mutation, another common cause of EGFR TKI resistance in NSCLC^[@B22],[@B23]^ ([Fig 3B](#F3){ref-type="fig"}). In a patient with *BRAF* V600E--mutant (and *NRAS*-negative) melanoma, we identified an *NRAS* G12R mutation in the CSF (patient 16), a genetic alteration known to promote acquired resistance to BRAF inhibition in melanoma.^[@B24]-[@B26]^ Both the *KRAS* G12A and the *NRAS* G12R mutations were not detected by Sequenom before therapy.

###### 

Drug-resistance mutations in patients whose central nervous system (CNS) disease progresses during kinase inhibitor therapy. (A) Summary of genomic profiling results from cerebrospinal fluid (CSF) and other tumor sites in patients in whom progressive CNS disease developed during treatment with the indicated kinase inhibitors. (B) Disease timeline and brain magnet resonance images (MRIs) from a patient with *EGFR*-mutant NSCLC (patient 3) who presented with leptomeningeal metastasis (baseline MRI, arrows), responded to erlotinib (follow-up MRI at 26 months), was found to have a secondary *EGFR* mutation (T790M) in a bone metastasis, and developed progressive CNS disease (brain MRIs at 32 and 35 months) that did not respond to second-generation EGFR TKI or pulse erlotinib. CSF cell-free DNA (cfDNA) identified an *EGFR* T790M mutation. (C) Disease timeline and brain MRIs from a patient with *EGFR*-mutant NSCLC (patient 4) who presented with brain metastases (baseline MRI), responded to erlotinib (follow-up brain MRI at 2 months and brain CT scan at 9 months), and later developed progressive brain metastases. Molecular profiling of the recurrent lung tumor showed a secondary *EGFR* mutation (T790M), whereas CSF cfDNA identified an activating *KRAS* mutation (and the absence of T790M). Sequenom mass spectrometry genotyping was performed for specific mutations in eight genes: *AKT1*, *BRAF*, *EGFR*, *ERBB2*, *KRAS*, *MEK1* (*MAP2K1*), *NRAS*, and *PIK3CA*. ALK, anaplastic lymphoma kinase; AMP, amplification; BrCa, breast cancer; CT, computed tomography; del, deletion; EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; IMPACT, Integrated Molecular Profiling of Actionable Cancer Targets; ND, not determined; NSCLC, non--small-cell lung cancer; PCR, polymerase chain reaction; pert, pertuzumab; T-DM1, trastuzumab emtansine; TKI, tyrosine kinase inhibitor; trast, trastuzumab; WBRT, whole-brain radiotherapy.
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Sequencing of CSF from two additional patients identified candidate drug-resistance mutations, but the relationship to clinical drug resistance was more ambiguous. Progressive CNS disease eventually developed in one patient (patient 8) with *HER2*-amplified breast cancer who received multiple HER2-targeted therapies (trastuzumab, rhuMAb 2C4, and lapatinib) and who was found to harbor an activating mutation in the catalytic subunit of phosphatidylinositol 3-kinase (PI3K; *PIK3CA* H1047R) in CSF cfDNA, a potential cause of trastuzumab resistance in breast cancer.^[@B27],[@B28]^ The allelic frequency of the PIK3CA mutation was considerably higher in the CSF sample (38%) than in the pretreatment primary tumor (4%). CSF from patient 15 with *BRAF* V600E--mutant melanoma showed a homozygous deletion of *PTEN*, but the primary tumor as not available to ascertain whether this genetic alteration occurred only in the CSF.

We also identified clinically relevant genomic alterations in CSF cfDNA from patients whose primary tumors could not be profiled because of limited access to tumor tissue, insufficient tumor content, or DNA quantity. For example, the CSF cfDNA from patient 18 with gastroesophageal carcinoma whose available tumor tissue was not adequate for molecular profiling (Appendix [Fig A4](#FA.4){ref-type="fig"}, online only) harbored multiple somatic copy number alterations, including the loci for the receptor tyrosine kinases HER2 and fibroblast growth factor receptor 2, which are established drug targets in cancer and frequently amplified in this cancer type.^[@B29]^ Similarly, we identified *PDGFRA* amplification in a patient with a brainstem glioma^[@B30]^ that could not be biopsied because of the precarious tumor location (Appendix [Figs A5](#FA.5){ref-type="fig"} and [A6](#FA.6){ref-type="fig"}, online only).

Sequencing of CSF cfDNA identified mutations in six of 12 (50%) patients with primary brain tumors despite that the CSF was negative for malignant cells in most (n = 11) of these patients. In one of these patients ([Fig 4A](#F4){ref-type="fig"}), we were able to compare the pattern of mutations in CSF cfDNA with tumor profiling results obtained from the original tumor specimen and a second specimen obtained 3 weeks after CSF collection. Mutations in four genes (*IDH1*, *TP53*, *ATRX*, and *TGFBR1*) were detected in all three samples, but only the later samples harbored additional, but distinct mutations that activate the PI3K pathway, namely a truncating mutation in the *PTEN* tumor suppressor gene (CSF cfDNA) and an oncogenic hotspot mutation in the catalytic subunit of PI3K (recurrence tumor specimen). These data illustrate spatial heterogeneity within the CNS with evolutionary convergence on the PI3K signaling pathway during glioma progression. In another patient with 1p/19q codeleted oligodendroglioma^[@B31],[@B32]^ ([Fig 4B](#F4){ref-type="fig"}), CSF cDNA profiling 7.4 years after the initial diagnosis identified \> 400 nonsynonymous single nucleotide variants. These mutations almost entirely represented C\>T/G\>A nucleotide changes, a mutation pattern that has been associated with exposure to temozolomide therapy in glioma.^[@B33]^

![Tumor evolution in patients with primary brain tumors. (A) Spatial and temporal heterogeneity among samples obtained at diagnosis, at recurrence, and from cerebrospinal fluid (CSF) in patient 42 with recurrent glioblastoma. CSF cell-free DNA harbors a *PTEN* R130\* mutation (variant allele frequency, 0.25), whereas resection 2 harbors a *PIK3CA* H1047R mutation (variant allele frequency, 0.441). (B) CSF molecular profile for patient 45 with anaplastic oligodendroglioma contains the *IDH1* R132H mutation and 1p/19q deletion found in tissue resection 2 as well as 454 nonsilent somatic mutations. Four hundred forty-eight SNVs represent C\>T/G\>A mutations that demonstrate TMZ-induced mutagenesis. Carbo, carboplatin; CCNU, lomustine; rhuMAB VEGF, bevacuzumab; RT, radiotherapy; SNV, single nucleotide variant; TMZ, temozolomide.](JCO666487f4){#F4}

DISCUSSION {#s11}
==========

Cancers involving the CNS are associated with exceptional morbidity and mortality. The development of a precision medicine paradigm for these cancers is hampered by difficulty in accessing tumor tissue. The current study expands on recent technical reports^[@B9]^ and demonstrates the feasibility of deriving a comprehensive molecular profile from CSF collected through lumbar puncture, a procedure that often is done in the physician's office. Key aspects of our approach included the use of CSF cfDNA, which obviated the need for additional steps to enrich for tumor cells and a clinically validated next-generation sequencing platform capable of identifying all classes of cancer-associated mutations (base substitutions, insertions, deletions, fusions, gene copy number alterations). Mutation calling and copy number analysis were performed by using an automated bioinformatics pipeline with consistent criteria and thresholds across all samples. These modifications from prior approaches help us to identify tumor-associated DNA without the need for invasive surgery, in patients with cytology-negative CSF, and without prior knowledge of molecular alterations in the primary tumor. This approach could be implemented in most health care environments that already collect and process CSF as part of routine clinical practice.

CSF represents just one of many bodily fluids from which tumor-derived cfDNA can be isolated for molecular profiling. Blood plasma has received the greatest attention in recent years for its potential to serve as a "liquid biopsy" for patients with solid tumors.^[@B34],[@B35]^ Many groups have demonstrated the utility of plasma cfDNA to facilitate noninvasive mutation profiling, monitoring response to therapy, and the identification of emergent resistance mutations in patients with advanced disease.^[@B2],[@B36]-[@B38]^ These studies have encompassed multiple tumor types, including breast cancer, lung cancer, and prostate cancer.^[@B37],[@B39],[@B40]^ Furthermore, plasma DNA shows promise at earlier stages of disease as a prognostic for the risk of recurrence after surgery and even as a means for early detection of cancer.^[@B41],[@B42]^ Whereas early studies used targeted assays to longitudinally monitor individual prespecified mutations, such as BEAMing^[@B43]^ and digital droplet PCR, next-generation sequencing technologies have demonstrated the potential to reveal not only novel mutations, but also gene amplifications and fusions.^[@B44]-[@B46]^

One major challenge associated with plasma cfDNA sequencing is the need to detect mutations at very low allele frequencies. Tumor-derived DNA typically constitutes only a small fraction of all cfDNA in plasma due to the relatively high background of normal DNA from nonmalignant cells. Consequently, key oncogenic mutations may occur in only 1% or even 0.1% of molecules from a given genomic locus, requiring very deep sequence coverage to achieve sufficient sensitivity for detecting these mutations. This has also necessitated modifications to sequencing assays in order to maintain high specificity in the presence of sequencing errors and artifacts. Examples include Safe-SeqS^[@B47]^ and Duplex Sequencing,^[@B48]^ both of which use unique molecular identifiers to reduce errors through replicate sequence reads from the same template molecule. Importantly, we found that these approaches were not necessary for CSF cfDNA profiling. Although cfDNA yields were generally low after nucleic acid extraction from CSF, we observed that the fraction of tumor-derived cfDNA was generally high due to the relative absence of background normal DNA. As a result, we were able to readily detect somatic mutations even in cases where we only achieved modest sequence coverage (\< 100×).

We found that tumor-associated DNA can be detected in CSF in a substantial number of patients with primary brain tumors, which agrees with a recent study that collected CSF intraoperatively from patients with primary brain tumors^[@B8]^ and suggests that collection and genomic profiling of CSF should be considered more broadly in patients with these tumors because it might provide new insights into tumor evolution and drug response. Because brain metastases and primary brain tumors are often inaccessible to surgery, we focused on an approach that did not require surgery for CSF collection. The current study also points to other scenarios where liquid biopsies and genomic profiling of CSF might guide clinical decision making, such as with leptomeningeal metastasis. This condition is notoriously difficult to diagnose with current methods and is associated with extraordinary morbidity and mortality.^[@B49],[@B50]^ Similarly, CSF liquid biopsies could be informative in patients with multiple brain metastases, which are rarely biopsied but can harbor mutations not observed in the primary tumor.^[@B51]^

Tumor growth in the CNS despite systemic disease control remains a major clinical challenge. It is often unclear whether the CNS represents a sanctuary site, shielding malignant cells from target therapies, or whether select mutations render malignant cells more likely to successfully colonize the CNS. Our data suggest caution when using systemic genotyping results to predict the clinical response of CNS disease to targeted therapies. For extracranial sites, on-treatment biopsy specimens have shown several resistance mechanisms, including mutations that can restore signaling downstream of the target kinase, activate an alternative signaling pathway, or impair drug binding to the target kinase.^[@B52]^ The molecular basis of kinase inhibitor resistance in the CNS is unknown and widely attributed to inadequate drug penetration into the CNS.^[@B28]-[@B33],[@B49]-[@B58]^ The current data suggest a more nuanced view of this common clinical problem because we identified a genetic explanation for drug resistance in at least four of 12 patients (33%). The current findings may explain the clinical experience that only a fraction of patients with acquired kinase inhibitor resistance in the CNS respond to an increase in the drug dose or intrathecal drug administration designed to overcome reduced penetration of drug into the CNS.^[@B59]-[@B62]^ They are also consistent with the recent identification of mutations in surgically resected brain tumor metastases that were not found in the primary tumors of the same patients.^[@B51]^

Our findings suggest that CSF sequencing could substantially increase the number of patients who are eligible for genotype-directed cancer therapy, including patients whose primary tumor could not be successfully sequenced and patients who are poor candidates for neurological surgery due to medical comorbidities or tumor location in neurologically critical areas (eg, brainstem). Our study also suggests that cfDNA analysis in the CSF could be a suitable biomarker to monitor clinical response to therapy, analogous to plasma cfDNA, an area that will warrant further prospective evaluation. Together with the cited studies, this study demonstrates that genomic analysis of CSF by using a sufficiently sensitive and comprehensive platform may be useful in facilitating the diagnosis of tumor in the CNS, monitor the evolution of the cancer genome during treatment of CNS cancers, guide the choice of second-line agents, and perhaps identify pathways that are uniquely associated with cancer spread to the CNS.
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![Copy number plot for patient 12. cfDNA, cell-free DNA; CSF, cerebrospinal fluid; Pt, patient ID.](JCO666487app1){#FA.1}

![Detection of *EML4-ALK* gene fusion in cerebrospinal fluid (CSF) cell-free DNA (cfDNA) and pellet DNA for patient 7. Pt, patient ID.](JCO666487app2){#FA.2}

![(A) DNA input, (B) library yield, and (C) unique mean sequence coverage.](JCO666487app3){#FA.3}

![Patient 18: the copy number plot (left panel) showing multiple somatic copy number alterations, including the loci for the receptor tyrosine kinases HER2 and FGFR2 and a brain MRI (right panel) with arrows pointing toward leptomeningeal metastases. CSF, cerebrospinal fluid; FGFR2, fibroblast growth factor receptor 2; HER2, human epidermal growth factor receptor 2.](JCO666487app4){#FA.4}

![CSF cell-free DNA profiling of glioblastoma for patient 46. CSF, cerebrospinal fluid; RT, radiotherapy; TMZ, temozolomide.](JCO666487app5){#FA.5}

![Patient 47: the copy number plot (left panel) showing amplification of the *PDGFRA* gene locus and a brain MRI (right panel) with arrows pointing toward the enhancing tumor in the brainstem.](JCO666487app6){#FA.6}

###### 

Comparison Between cfDNA and Cell Pellet DNA From CSF to Identify Specific Genetic Alterations

![](JCO666487ta1)

         Primary Tumor         CSF cfDNA             CSF Cell Pellet                                                                                                         
  ------ --------------------- --------------------- ----------------- ------- --------------------------------- ----- ------- ------- ------------------------------------- -----
  Pt05   Lung adenocarcinoma   *KRAS* G12C           105               1,050   96% of reads (1,111 of 1,154)     Yes   93      1,252   30% of reads (349 of 1,165)           Yes
  Pt01   Lung adenocarcinoma   *EGFR* L858R          13                247     56% of reads (215 of 384)         Yes   33      427     10% of reads (45 of 439)              Yes
  Pt07   Lung adenocarcinoma   *EML4-ALK* fusion     90                615     102 reads                         Yes   1,328   980     102 reads                             Yes
  Pt06   Lung adenocarcinoma   *ALK* rearrangement   14.5              177     39 reads                          Yes   86      784     14 reads                              Yes
  Pt08   Breast cancer         *HER2* positive       21.5              430     AMP (average log2 ratio, 3.51)    Yes   96      846     Non-AMP (average log2 ratio, 0.34)    No
  Pt12   Breast cancer         *PTEN* negative       50                800     Del (average log2 ratio, −2.97)   Yes   5       78      Non-del (average log2 ratio, −0.05)   No
  Pt14   Melanoma              *BRAF* V600E          9                 38      24% of reads (15 of 63)           Yes   74      646     0% of reads (2 of 652)                No
  Pt15   Melanoma              *BRAF* V600E          7.8               194     96% of reads (364 of 381)         Yes   290     964     89% of reads (1,222 of 1,375)         Yes

NOTE. All eight patients with cancer had clinically documented leptomeningeal metastasis from the primary tumor shown in column 2. For each patient, mutation detection focused on a specific alteration previously identified in the primary tumor tissue (column 3). Shown is the supporting evidence for the known genomic alteration in CSF. Alterations were detected in all eight CSF cfDNA samples and five CSF pellet DNA samples.

Abbreviations: ALK, anaplastic lymphoma kinase; AMP, amplification; cfDNA, cell-free DNA; del, deletion; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2.

###### 

Variables Included in Statistical Analysis

![](JCO666487ta2)

                                                   CSF Tumor-Derived cfDNA Cohort (n = 20), No. (%)   Absent Tumor-Derived CSF cfDNA Cohort (n = 21), No. (%)   *P*
  ------------------------------------------------ -------------------------------------------------- --------------------------------------------------------- -----
  Age, mean (SD)                                   55.0 (11.5)                                        55.4 (11.6)                                               .92
  Sex                                                                                                                                                           
   Male                                            9 (45)                                             8 (38)                                                    .65
   Female                                          11 (55)                                            13 (62)                                                   
  Tumor histology                                                                                                                                               
   Breast                                          6 (30)                                             5 (24)                                                    .42
   Lung                                            7 (35)                                             4 (19)                                                    
   Melanoma                                        3 (15)                                             3 (14)                                                    
   Others                                          4 (20)                                             9 (43)                                                    
  Anatomic location                                                                                                                                             
   Brain metastasis                                                                                                                                             
   Supratentorial                                  7 (35)                                             7 (33)                                                    .06
   Infratentorial                                  3 (15)                                             0 (0)                                                     
   Supra- and infratentorial                       7 (35)                                             4 (19)                                                    
   No brain metastasis                             3 (15)                                             10 (48)                                                   
  Distant metastasis                                                                                                                                            
   Yes                                             19 (95)                                            16 (76)                                                   .09
   No                                              1 (5)                                              5 (24)                                                    
  Prior CNS surgery                                                                                                                                             
   Yes                                             8 (40)                                             3 (14)                                                    .06
   No                                              12 (60)                                            18 (86)                                                   
  Chemotherapy at the time of CSF collection                                                                                                                    
   Yes                                             17 (85)                                            14 (67)                                                   .17
   No                                              3 (15)                                             7 (33)                                                    
  Radiation therapy to CNS before CSF collection                                                                                                                
   Yes                                             12 (60)                                            9 (43)                                                    .27
   No                                              8 (40)                                             12 (57)                                                   

NOTE. This cohort excluded patients with primary brain tumors. See text and [Tables 1](#T1){ref-type="table"} and [A1](#TA.1){ref-type="table"} for details. Abbreviation: cfDNA, cell-free DNA.

###### 

Characteristics of 53 Patients, Including CSF Cytology and Primary Tissue Diagnosis, for Which CSF cfDNA Was Extracted and Analyzed

![](JCO666487ta3)

  Patient No.            Age   Sex   Tumor Type                        CSF Cytology   CNS Involvement   Other Mets   Original Specimen (Molecular Path)                                          CSF (MSK-IMPACT)
  ---------------------- ----- ----- --------------------------------- -------------- ----------------- ------------ --------------------------------------------------------------------------- ---------------------------------------------------------------
  Solid tumors                                                                                                                                                                                   
   1                     40    M     Lung adenocarcinoma               Negative       BM                Yes          *EGFR* L858R (bone, Sequenom)                                               *EGFR* L858R (56%)
   2                     52    M     Lung adenocarcinoma               Positive       BM                No           *EGFR* L858R (lung, Sequenom)                                               *EGFR* T790M (2.5%), EGFR L858R (76%)
   3                     51    F     Lung adenocarcinoma               Positive       BM                Yes          *EGFR* exon 19 del (chest wall, Sequenom)                                   *EGFR* T790M (2.8%), *EGFR* 745_750 del (37%)
   4                     75    M     Lung adenocarcinoma               Negative       BM                Yes          *EGFR* L858R (lung, Sequenom)                                               *KRAS* G12A (19%), *EGFR* L858R (65%)
   5                     71    F     Lung adenocarcinoma               Positive       BM                Yes          *KRAS* G12C (c34 G\>T) (lung, Sequenom)                                     *KRAS* G12C (96%), *CDKN2B* del (log2, −2.9)
   6                     30    M     Lung adenocarcinoma               Positive       BM                Yes          *ALK* rearrangement (lung, ND)                                              *EML4-ALK* fusion (39 reads)
   7                     73    F     Lung adenocarcinoma               Positive       LM                Yes          *EML4-ALK* fusion (lung, FM)                                                *EML4-ALK* fusion (102 reads)
   8                     38    F     Breast cancer                     Positive       BM                Yes          *HER2* AMP (breast, FISH)                                                   *PIK3CA* H1047R (38%), *HER2* AMP (log2, 3.5)
   9                     56    F     Breast cancer                     Positive       BM                Yes          *HER2* AMP (breast, FISH)                                                   *HER2* AMP (log2, 2.6)
   10                    53    F     Breast cancer                     Positive       BM                Yes          *HER2* positive (breast, IHC 3+)                                            *HER2* AMP (log2, 2.6)
   11                    59    F     Breast cancer                     Positive       BM                Yes          No molecular profiling performed                                            *EGFR* AMP (log2, 3.1), *PIK3CA* H1047R (28%)
   12                    60    F     Breast cancer                     Positive       BM                Yes          *TP53* V272M (56%), *PTEN* del (log2, −2.0; lymph node, MSK-IMPACT)         *TP53* V272M (81%), *PTEN* del (log2, −2.97)
   13                    59    F     Breast cancer                     Positive       BM                Yes          ER positive, PR/HER2 negative; thyroid metastasis, IHC)                     *PIK3CA* E545K (26%)
   14                    45    M     Melanoma                          Positive       BM                Yes          *BRAF* V600E (skin, ND)                                                     *BRAF* V600E (24%)
   15                    68    M     Melanoma                          Positive       LM                Yes          *BRAF* V600E (skin, ND)                                                     *PTEN* del (log2, −XYZ), *BRAF* V600E (96%)
   16                    57    F     Melanoma                          Positive       BM                Yes          *BRAF* V600E (skin, ND)                                                     *NRAS* G12R (3%), *PTEN* del (log2, −3.0), *BRAF* V600E (47%)
   17                    55    M     Bladder cancer                    Positive       BM                Yes          No molecular profiling performed                                            *AKT2* AMP (log2, 3.37), *TP53* R158L (43%)
   18                    50    M     Gastroesophageal                  Positive       LM                Yes          No molecular profile (MSK-IMPACT failure)                                   *HER2* AMP (log2, 2.4), *FGFR2* (log2 3.6)
   19                    54    M     Neuroendocrine, unknown primary   Negative       BM                Yes          No molecular profiling performed                                            *MYCN* AMP (log2, 4.1)
   20                    55    F     Ovarian cancer                    Negative       BM                Yes          *BRCA1* insC (blood, Myriad Genetics laboratory)                            *BRCA1* Q1756fs (53%), *CDKN2B* del (log2, −2.1)
   21                    70    F     Ovarian cancer                    Negative       LM                Yes          No molecular profiling performed                                            Negative
   22                    36    F     Breast cancer                     Negative       BM                Yes          No molecular profiling performed                                            Negative
   23                    50    F     Breast cancer                     Negative       BM                Yes          *HER2* AMP (breast, FISH)                                                   Negative
   24                    49    F     Breast cancer                     Negative       BM                Yes          *ESR1* Y537S (62%), *CCND1* AMP (log2, 1.5; breast, MSK-IMPACT)             Negative
   25                    32    F     Breast cancer                     Negative       BM                Yes          *RB1* L343Sfs\*3 (liver, MSK-IMPACT)                                        Negative
   26                    40    F     Breast cancer                     Negative       BM                Yes          *PIK3CA* R108 del (39%), *CCND1* AMP (log2, 1.0; soft tissue, MSK-IMPACT)   Negative
   27                    63    F     Lung adenocarcinoma               Negative       BM                Yes          No molecular profiling performed                                            Negative
   28                    66    M     Lung adenocarcinoma               Negative       BM                Yes          No molecular profiling performed                                            Negative
   29                    66    F     Small-cell lung cancer            Negative       BM                Yes          No molecular profiling performed                                            Negative
   30                    58    F     Lung adenocarcinoma               Negative       Negative          Yes          *ALK* rearrangement (lung, FISH)                                            Negative
   31                    56    M     Melanoma                          Negative       BM                Yes          *BRAF* V600E (skin, Sequenom)                                               Negative
   32                    54    M     Melanoma                          Negative       BM                Yes          *BRAF* V600K (lymph node, Sequenom)                                         Negative
   33                    37    F     Melanoma                          Negative       Negative          Yes          *NRAS* (lung, Sequenom)                                                     Negative
   34                    55    F     Thyroid cancer                    Negative       BM                Yes          *NRAS* TP53 (thyroid, PCR)                                                  Negative
   35                    54    F     Thyroid cancer                    Negative       Negative          No           No molecular profiling performed                                            Negative
   36                    76    M     Rectal cancer                     Negative       Negative          Yes          No molecular profiling performed                                            Negative
   37                    58    M     Prostate cancer                   Negative       Negative          No           No mutation found (prostate, MSK-IMPACT)                                    Negative
   38                    67    M     Prostate cancer                   Negative       Negative          Yes          *NOTCH1* R1758H (13%; prostate, MSK-IMPACT)                                 Negative
   39                    64    M     Renal cell carcinoma              Negative       Negative          No           No molecular profiling performed                                            Negative
   40                    58    M     Renal cell carcinoma              Negative       Negative          No           No molecular profiling performed                                            Negative
   41                    57    F     Liposarcoma                       Negative       Negative          No           No molecular profiling performed                                            Negative
  Primary brain tumors                                                                                                                                                                           
   42                    24    M     Anaplastic astrocytoma            Negative       N/A               No           *IDH1* R132H (IHC), *PIK3CA* H1047R                                         *IDH1* R132H (38%), *PTEN* R130\* (25%)
   43                    65    M     Glioblastoma                      Negative       N/A               No           No molecular profiling performed                                            *PIK3CA* V344M (6%)
   44                    63    M     Glioblastoma                      Negative       N/A               No           *PTEN* loss (IHC)                                                           *PTEN* Y336_F337 delins\* (14%), *EGFR* AMP (log2, 3.4)
   45                    39    F     Anaplastic oligodendroglioma      Negative       N/A               No           *IDH1* R132H (IHC), 1p/19q del (FISH)                                       *IDH1* R132H (44%), 1p/19q del (log2, −0.8)
   46                    66    M     Glioblastoma                      Negative       N/A               No           *PTEN* loss, *CDK4* AMP, *CLI1* AMP, *TP53*, *TERT*, *SPTA1* (FM)           *CDK4* AMP (log2, 2.4)
   47                    29    M     Brainstem glioma                  Positive       N/A               No           No molecular profiling performed                                            *PDGFRA* AMP (log2, 2.0), *CDKN2B* del (log2, −3.0)
   48                    78    M     Glioblastoma                      Negative       N/A               No           No molecular profiling performed                                            Negative
   49                    58    F     High-grade glioma                 Negative       N/A               No           No molecular profiling performed                                            Negative
   50                    38    M     Oligodendroglioma                 Negative       N/A               No           No molecular profiling performed                                            Negative
   51                    35    F     Anaplastic ependymoma             Negative       N/A               No           *CDKN2A* Y44\* (8%; MSK-IMPACT)                                             Negative
   52                    71    M     Anaplastic oligodendroglioma      Negative       N/A               No           1p/19q del (FISH)                                                           Negative
   53                    65    M     Anaplastic oligodendroglioma      Negative       N/A               No           *IDH1* R132H (IHC), p19q del (FISH)                                         Negative

Abbreviations: AMP, amplification; BM, brain metastasis; del, deletion; delins, deletion/insertion; EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization; FM, Foundation Medicine; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; LM, leptomeningeal metastasis; Mets, metastases; MSK-IMPACT, Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets; N/A, not applicable; ND, not determined; PCR, polymerase chain reaction.
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